SCIDA

Scida

Study and development of new pro- and prebiotic products for the prevention and treatment of inflammatory diseases such as irritable bowel syndrome and atopic dermatitis

Structure

DURATION

5 months

BUDGET

€ 6.559.787,51

FUNDING

€ 3.696.825,74

Project mission

 The project’s action focuses on the identification and validation of new pro and prebiotic drugs used to prevent and treat inflammatory pathologies such as irritable bowel syndrome and atopic dermatitis. Both these diseases affect a relevant portion of Italian population causing a negative impact on the patients’ ordinary life. The project thus develops two research lines with the aim at discovering new medicines that restore the microbiota’s balance and improve the intestinal flora. First a comprehensive database will be created in order to sum up the most relevant data that enable to the identification of specific targets for the early treatment; and secondly, the discovered pro and prebiotics will be validated to allow the scale up and industrialization process.  

Project Partners

ASST Sacco Fatebenefratelli
Bict srl
Naicons
Sanofi
Roelmi hpc
Università degli Studi di Milano
Istituto di Tecnologie Biomediche
Address

Legal and administrative residence
Via Gaudenzio Fantoli 16/15
20138 Milano